Innovent expands Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-squamous NSCLC patients

By Public Technologies
  • Innovent Biologics expanded its global Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-squamous NSCLC patients.
  • No clinical results were presented; the study will evaluate whether IBI363 improves outcomes versus docetaxel in immunotherapy-resistant disease.
  • The trial now runs as two independent substudies, each testing IBI363 monotherapy in previously treated unresectable or metastatic NSCLC.
  • IBI363 is a first-in-class IL-2/PD-1 bispecific fusion protein partnered with Takeda for global development and US co-commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609272000PR_NEWS_USPR_____CN55963) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk